Web5 Mar 2004 · Judge tells of murder plots to block Dutroux investigation. By Ambrose Evans-Pritchard in Arlon 05 March 2004 • 12:01am. Jean-Marc Connerotte. The Belgian judge … WebThe author collected the following names in the 2006-2007 period from the then still unavailable "Dutroux" X-Dossiers summary file, the actual Dutroux Dossier (what remained of it) and other cases - and wrote biographies with each name.These biographies actually served as data dumps in preparation for the main "Beyond Dutroux" article.. Contents
Phase III study of ACVBP versus ACVBP plus rituximab for ... - CORE
WebPierre G Coulie and Thierry Connerotte In recent years, several clinical trials have involved the cacy, and that the function of these lymphocytes could vaccination of cancer patients … Web1 Jan 2013 · Abstract peer reviewedBackground The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparaison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for Young patients with localized diffuse large B-cell lymphoma (DLBCL) was … gain cubase
Functions of Anti-MAGE T-Cells Induced in Melanoma Patients …
WebThierry Seurre M Veteran 6 Pascal Durniak M Scratch 7 Georges Degans M Scratch 8 Clément Gaboriau M Scratch 9 Samuel Fromont M Scratch 10 David Demor ... Thierry … WebVaios Karanikas, Christophe Lurquin, Didier Colau, Nicolas van Baren, Charles De Smet, Bernard Lethé, Thierry Connerotte, Véronique Corbière, Marie-Ange Demoitié, Danielle Liénard, Brigitte Dréno, Thierry Velu, Thierry Boon, Pierre G. Coulie, Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after ... WebWe describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide encoded by gene MAGE-A3 and presented by HLA-A1. The frequency of anti-MAGE-3.A1 CTLp was 5 x 10(-7) of the blood CD8 cells, with a dominant clonotype which was present in six out of seven independent anti-MAGE-3.A1 … gain crunchy